Hepatitis B: Explosion of New Knowledge

Gastroenterology

Volumn 133, Issue 5, 2007, Pages 1718-1721

  Keeffe, Emmet B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA2B INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIBODY; IMMUNOMODULATING AGENT; LAMIVUDINE; NUCLEOSIDE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; HEPATITIS B VIRUS; HEPATITIS B VIRUS INFECTION REACTIVATION; HUMAN; IMMUNE CLEARANCE; IMMUNOLOGICAL TOLERANCE; INACTIVE HEPATITIS B SURFACE ANTIGEN CARRIER STATE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RISK FACTOR; UNITED STATES; VIRUS INFECTION; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; GENOTYPE; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; LAMIVUDINE; PHOSPHONIC ACIDS;

EID: 35648963723     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.09.048     Document Type: Editorial

References (23)

1. Ganen D., and Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
2. Yim H.J., and Lok A.S.F. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43 (2006) S173-S181
3. Keeffe E.B., Dieterich D.T., Han S.B., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
4. Lok A.S.F., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
5. Lok A.S.F. Navigating the maze of hepatitis B treatments. Gastroenterology 132 (2007) 1586-1594
6. McQuillan G.M., Coleman P.J., Kruszon-Moran D., et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 89 (1999) 14-18
7. US Census Bureau State and County Quickfacts: 01 February 2005. Available at: http://quickfacts.census.gov/qfd/states/00000.html. Accessed September 16, 2007.
8. Phase III study evaluating Gilead's Viread for the treatment of chronic hepatitis B virus meets primary endpoint [press release on the Internet]. Updated June 6, 2007. Available at: www.gilead.com/pr_1012569. Accessed September 16, 2007.
9. Second phase III study evaluating Gilead's Viread for the treatment of chronic hepatitis B virus meets primary endpoint [press release on the Internet]. Updated June 25, 2007. Available at: www.gilead.com/pr_1018988. Accessed September 16, 2007.
10. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
11. Arora G., and Keeffe E.B. Chronic hepatitis B with advanced hepatic fibrosis or cirrhosis: impact of antiviral therapy. Rev Gastroenterol Disord 7 (2007) 63-73
12. Ghany M., and Liang T.J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132 (2007) 1574-1585
13. Livingston S.E., Simonetti J.P., Bulkow L.R., et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 133 (2007) 1452-1457
14. Chu C.M., and Liaw Y.F. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 133 (2007) 1458-1465
15. Gish R.G., Lok A.S., Chang T.T., et al. Entecavir therapy up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133 (2007) 1437-1444
16. Lampertico P., Viganò M., Manenti E., et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133 (2007) 1445-1451
17. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
18. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
19. Kramvis A., Kew M., and Francois G. Hepatitis B virus genotypes. Vaccine 23 (2005) 2409-2423
20. Liu C.H., and Kao J.H. Hepatitis B virus genotypes: what should the clinician know?. Current Hepatitis Reports 6 (2007) 17-23
21. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
22. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
23. Colonno R.J., Rose R.E., Pokornowski K., et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 46 (2007) S294 [abstract 781]